FDG-PET/CT response evaluation during EGFR-TKI treatment in patients with NSCLC.
作者： Matthijs H van Gool , Tjeerd S Aukema , Koen J Hartemink , Renato A Valdés Olmos , Harm van Tinteren
关键词:
摘要: Over recent years, [18F]-fluorodeoxyglucose positron emission tomography acquired together with low dose computed (FDG-PET/CT) has proven its role as a staging modality in patients non-small cell lung cancer (NSCLC). The purpose of this review was to present the evidence use FDG-PET/CT for response evaluation NSCLC, treated epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKI). All published articles from 1 November 2003 2013 reporting on 18F-FDG-PET during EGFR-TKI treatment NSCLC were collected. In total 7 studies, including data 210 eligible analyses. Our report shows that therapy potential targeted NSCLC. is associated clinical and radiologic survival. Furthermore monitoring can be performed early 1-2 wk after initiation treatment. Patients substantial decrease metabolic activity will probably benefit continued If does not occur within first weeks treatment, may spared (further) unnecessary toxicity ineffective Refining FDG-PET criteria help clinician decide continuation or discontinuation
sci-hub.st 参考文章(33)
Didier Lardinois, Walter Weder, Thomas F. Hany, Ehab M. Kamel, Stephan Korom, Burkhardt Seifert, Gustav K. von Schulthess, Hans C. Steinert, Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography. The New England Journal of Medicine. ,vol. 348, pp. 2500- 2507 ,(2003) , 10.1056/NEJMOA022136
M.E.R. O’Brien, J.S. Myerson, J.I.G. Coward, M. Puglisi, L. Trani, A. Wotherspoon, B. Sharma, G. Cook, S. Ashley, R. Gunapala, S. Chua, S. Popat, A phase II study of ¹⁸F-fluorodeoxyglucose PET-CT in non-small cell lung cancer patients receiving erlotinib (Tarceva); objective and symptomatic responses at 6 and 12 weeks. European Journal of Cancer. ,vol. 48, pp. 68- 74 ,(2012) , 10.1016/J.EJCA.2011.10.033
Michael P MacManus, John F Seymour, Rodney J Hicks, Overview of early response assessment in lymphoma with FDG-PET. Cancer Imaging. ,vol. 7, pp. 10- 18 ,(2007) , 10.1102/1470-7330.2007.0004
Linda Mileshkin, Rodney J. Hicks, Brett G.M. Hughes, Paul L.R. Mitchell, Veena Charu, Barbara J. Gitlitz, David Macfarlane, Benjamin Solomon, Lukas C. Amler, Wei Yu, Andrea Pirzkall, Bernard M. Fine, Changes in 18F-Fluorodeoxyglucose and 18F-Fluorodeoxythymidine Positron Emission Tomography Imaging in Patients with Non–Small Cell Lung Cancer Treated with Erlotinib Clinical Cancer Research. ,vol. 17, pp. 3304- 3315 ,(2011) , 10.1158/1078-0432.CCR-10-2763
Thomas J. Lynch, Daphne W. Bell, Raffaella Sordella, Sarada Gurubhagavatula, Ross A. Okimoto, Brian W. Brannigan, Patricia L. Harris, Sara M. Haserlat, Jeffrey G. Supko, Frank G. Haluska, David N. Louis, David C. Christiani, Jeff Settleman, Daniel A. Haber, Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib The New England Journal of Medicine. ,vol. 350, pp. 2129- 2139 ,(2004) , 10.1056/NEJMOA040938
Thomas Zander, Matthias Scheffler, Lucia Nogova, Carsten Kobe, Walburga Engel-Riedel, Martin Hellmich, Irini Papachristou, Karin Toepelt, Andreas Draube, Lukas Heukamp, Reinhard Buettner, Yon D. Ko, Roland T. Ullrich, Egbert Smit, Ronald Boellaard, Adriaan A. Lammertsma, Michael Hallek, Andreas H. Jacobs, Andreas Schlesinger, Karin Schulte, Silvia Querings, Erich Stoelben, Bernd Neumaier, Roman K. Thomas, Markus Dietlein, Jürgen Wolf, Early Prediction of Nonprogression in Advanced Non–Small-Cell Lung Cancer Treated With Erlotinib By Using [18F]Fluorodeoxyglucose and [18F]Fluorothymidine Positron Emission Tomography Journal of Clinical Oncology. ,vol. 29, pp. 1701- 1708 ,(2011) , 10.1200/JCO.2010.32.4939
M. R. Benz, K. Herrmann, F. Walter, E. B. Garon, K. L. Reckamp, R. Figlin, M. E. Phelps, W. A. Weber, J. Czernin, M. S. Allen-Auerbach, 18F-FDG PET/CT for Monitoring Treatment Responses to the Epidermal Growth Factor Receptor Inhibitor Erlotinib The Journal of Nuclear Medicine. ,vol. 52, pp. 1684- 1689 ,(2011) , 10.2967/JNUMED.111.095257
Corneline J. Hoekstra, Sigrid G. Stroobants, Egbert F. Smit, Johan Vansteenkiste, Harm van Tinteren, Pieter E. Postmus, Richard P. Golding, Bonne Biesma, Frans J.H.M. Schramel, Nico van Zandwijk, Adriaan A. Lammertsma, Otto S. Hoekstra, Prognostic Relevance of Response Evaluation Using [18F]-2-Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography in Patients With Locally Advanced Non–Small-Cell Lung Cancer Journal of Clinical Oncology. ,vol. 23, pp. 8362- 8370 ,(2005) , 10.1200/JCO.2005.01.1189
Andreas Stang, Hermann Pohlabeln, Klaus M. Müller, Ingeborg Jahn, Klaus Giersiepen, Karl-Heinz Jöckel, Diagnostic agreement in the histopathological evaluation of lung cancer tissue in a population-based case-control study Lung Cancer. ,vol. 52, pp. 29- 36 ,(2006) , 10.1016/J.LUNGCAN.2005.11.012
John R. Johnson, Martin Cohen, Rajeshwari Sridhara, Yeh-Fong Chen, Gene M. Williams, John Duan, Jogarao Gobburu, Brian Booth, Kimberly Benson, John Leighton, Li Shan Hsieh, Nallalerumal Chidambaram, Paul Zimmerman, Richard Pazdur, Approval summary for erlotinib for treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen. Clinical Cancer Research. ,vol. 11, pp. 6414- 6421 ,(2005) , 10.1158/1078-0432.CCR-05-0790